- Home
- ROOT vs CMPS Comparison
ROOT vs CMPS Comparison
Compare ROOT & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROOT | CMPS |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.6M | 724.5M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ROOT | CMPS |
|---|---|---|
| Price | $51.27 | $6.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $92.40 | $26.57 |
| AVG Volume (30 Days) | 278.6K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.96 | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,517,100,000.00 | N/A |
| Revenue This Year | $11.13 | N/A |
| Revenue Next Year | $13.29 | N/A |
| P/E Ratio | $21.88 | ★ N/A |
| Revenue Growth | ★ 28.95 | N/A |
| 52 Week Low | $40.91 | $2.25 |
| 52 Week High | $162.99 | $8.90 |
Technical Indicators
Market Signals| Indicator | ROOT | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 58.89 | 59.52 |
| Support Level | $41.78 | $5.87 |
| Resistance Level | $63.33 | $7.02 |
| Average True Range (ATR) | 2.44 | 0.31 |
| MACD | 1.19 | 0.13 |
| Stochastic Oscillator | 82.20 | 83.29 |
Price Performance
Historical ComparisonAbout ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.